Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC - Yu, H A; Oxnard, G R; Spira, A I (ASCO Meet Abstr, 2015)
(Suppl): abstract 8083